Larsen N E, Hansen L B
Department of Clinical Chemistry, Glostrup Hospital, Denmark.
Ther Drug Monit. 1989 Nov;11(6):642-6. doi: 10.1097/00007691-198911000-00005.
During a 3-month period, 52 paranoid psychotic inpatients were treated with perphenazine decanoate (Trilafon decanoate) in order to determine a treatment schedule ensuring perphenazine serum levels within the optimal range (2-6 nmol/L). All patients received 1 ml (108 mg) perphenazine decanoate on days 0, 7 and 21, after which the doses and intervals were individually adjusted according to the clinical condition. It was shown that the sum of 2 measurements of perphenazine concentration early during treatment, viz., on days 14 and 21, correlates strongly (r = 0.96) with the steady-state level obtained after 3 months. Consequently, a nomogram for dose and length of interval could be elaborated giving steady-state serum levels of perphenazine of about 4 nmol/L, i.e., in the middle of the optimal concentration range.
在为期3个月的时间里,对52名偏执型精神病住院患者使用癸酸奋乃静(Trilafon decanoate)进行治疗,以确定能确保奋乃静血清水平处于最佳范围(2 - 6纳摩尔/升)的治疗方案。所有患者在第0天、第7天和第21天均接受1毫升(108毫克)癸酸奋乃静治疗,之后根据临床状况对剂量和间隔时间进行个体化调整。结果显示,治疗早期(即第14天和第21天)的两次奋乃静浓度测量值之和与3个月后获得的稳态水平密切相关(r = 0.96)。因此,可以制定一个剂量和间隔时间长度的列线图,使奋乃静的稳态血清水平约为4纳摩尔/升,即处于最佳浓度范围的中间值。